Clinical Trial Update: A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma [Phase 2]

View source ↗

Summary

Phase II study of Imtox-25 in adults with refractory/relapsed CD25-positive Adult T Cell Leukemia/Lymphoma has been terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Leukemia
• T-cell Lymphoma

Drugs mentioned

• Imtox-25

Snippet

Sponsor: Amit Verma | Conditions: Adult T Cell Leukemia, Adult T Cell Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2023-06-09